A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with
unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.